Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Resiquimod. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 known ✓ | Q9NYK1 | 19/20 | 0.86 |
| ▸ | TLR8 known ✓ | Q9NR97 | 12/20 | 0.86 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Resiquimod SCHEMBL29358122 | 0.93 | TLR7 (1.00) | TLR7TLR8NUDT1 | |
| Resiquimod SCHEMBL21352711 | 0.93 | TLR7 (1.00) | TLR7TLR8NUDT1 | |
| Resiquimod SCHEMBL34159 | 0.93 | TLR7 (1.00) | TLR7TLR8NUDT1 | |
| Resiquimod SCHEMBL2262583 | 0.92 | TLR7 (0.98) | TLR7TLR8NUDT1 | |
| Resiquimod SCHEMBL2266073 | 0.92 | TLR7 (0.98) | TLR7TLR8NUDT1 | |
| SCHEMBL24880278 | 0.86 | TLR7 (0.88) | TLR7TLR8NUDT1 | |
| SCHEMBL17190818 | 0.86 | TLR7 (0.69) | TLR7TLR8NUDT1 | |
| SCHEMBL17190810 | 0.86 | TLR7 (0.66) | TLR7TLR8NUDT1 | |
| Resiquimod SCHEMBL22158700 | 0.86 | TLR7 (0.86) | TLR7TLR8NUDT1 | |
| SCHEMBL10298939 | 0.85 | TLR7 (0.78) | TLR7TLR8NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9447097-B2 | 4-amino-imidazoquinoline compounds | HOFFMANN-LA ROCHE INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-20160222010-A1 | 4-AMINO-IMIDAZOQUINOLINE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2016-08-04 | — | — | US | disclosed |
| US-9334268-B2 | 4-amino-imidazoquinoline compounds | HOFFMAN-LA ROCHE INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-20150299194-A1 | 4-AMINO-IMIDAZOQUINOLINE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2015-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160222010-A1 | 4-AMINO-IMIDAZOQUINOLINE COMPOUNDS | TLR4, TLR1, TLR5 | TLR7 4/4885TLR8 9/4885NUDT1 2019/4885 |
| US-20150299194-A1 | 4-AMINO-IMIDAZOQUINOLINE COMPOUNDS | TLR4, TLR1, TLR5 | TLR7 4/4885TLR8 9/4885NUDT1 2019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.